Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 35.57% ano a ano.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 47.56.
Avaliação Justa
O PE mais recente da empresa é -51.61, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 61.06M ações, um aumento de 0.03% em relação ao trimestre anterior.
Mantido por The Vanguard
O Super Investidor The Vanguard possui 6.10M ações desta empresa.